Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced on October 2, 2025 that it granted inducement awards on September 30, 2025 to nine new non-executive employees under its 2024 Inducement Equity Incentive Plan.

The grants consist of 247,000 stock options with an exercise price of $16.22 (equal to the closing price on the grant date) and 15,000 RSUs. Options vest 25% after one year then monthly over 3 years; RSUs vest 1/4 annually over four years. Awards were granted as inducements per Nasdaq Rule 5635(c)(4).

BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on September 30, 2025, Edgewise granted inducement stock options to purchase a total of 247,000 shares of Edgewise's common stock and awards of inducement restricted stock units ("RSU awards") covering a total of 15,000 shares of Edgewise's common stock to 9 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). 

Each inducement stock option has an exercise price of $16.22 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement RSU award shall vest as follows: one-fourth (1/4th) of the shares subject to each inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of the grant date, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302573999.html

SOURCE Edgewise Therapeutics

FAQ

What inducement awards did Edgewise (EWTX) grant on September 30, 2025?

Edgewise granted 247,000 stock options and 15,000 RSUs to nine new non-executive employees.

What is the exercise price of the Edgewise (EWTX) inducement options granted in Sept 2025?

Each option has an exercise price of $16.22, equal to the closing price on the grant date.

How do the inducement stock options for EWTX vest?

Options vest 25% after one year from start date, then 1/48th monthly thereafter subject to continued service.

What are the vesting terms for the Edgewise (EWTX) RSU inducement awards?

Each RSU award vests 1/4 on each of the first four anniversaries of the grant date, subject to continued service.

Why did Edgewise (EWTX) grant inducement awards on Sept 30, 2025?

Awards were granted as inducements to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Do the Sept 2025 inducement grants for Edgewise (EWTX) create immediate dilution?

The press release lists 262,000 potential shares (options + RSUs); it does not quantify existing shares outstanding or immediate dilution.